RxDoctor Payments Data

Arifulla Khan

Psychiatry · Bellevue, WANPI 1134241888

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $940 of the $1,340 with a category attached, or 70.2%. Pfizer accounts for 70.2% of it on its own, with 2 other manufacturers making up the rest. Among psychiatry clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,340in general payments, 2019–2025

Across 9 payments — averaging $148.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$940
  • Eli Lilly$360
  • Genentech, Inc.$40
$35,896,250in research payments, 2019–2025

Across 2,353 payments — averaging $15,256 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$19.8M
  • AbbVie$4.4M
  • Sage Therapeutics, LLC$1.8M
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1.6M
  • Pfizer$1.1M
  • Alkermes, Inc.$969K
  • plus $6.2M from 30 others

What the payments were for

  • Speaking & faculty fees$94070%
  • Travel & lodging$15011%
  • Food & beverage$21016%
  • Education$403%

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer1$940
Eli Lilly7$360
Genentech, Inc.1$40

How this compares

$1,340 in reported general payments places this provider in the 90th percentile of 576 psychiatry providers in Washington.

See all psychiatry providers in Washington

Other psychiatry in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →